Molina Healthcare (MOH) Q3 2026 Earnings Call Transcript

Molina Healthcare reported Q3 adjusted EPS of $0.89, down 52% year over year, and premium revenue of $10.5 billion, down 4%; its consolidated medical care ratio was 92.9%. Management reaffirmed 2026 guidance of at least $5.25 adjusted EPS and approximately $42 billion in premium revenue, while projecting 2027 premium revenue of at least $45 billion and preliminary adjusted EPS building blocks above $9.50. The outlook includes $1.3 billion of delayed Georgia and Texas contract revenue; management expects to realize $4 per share of embedded earnings in 2027, while elevated medical costs and anticipated Medicaid membership attrition remain risks.

Analysis

MOH’s 2027 earnings bridge is more execution-sensitive than the headline EPS building block suggests: roughly $4/share of the step-up comes from discrete contract/product items, not demonstrated improvement in the legacy Medicaid book. Florida’s move from a projected 5% pre-tax loss to breakeven depends on operational gains beyond one-time reserves; a miss would undermine both earnings and confidence in management’s broader contract-ramp playbook. The underlying Medicaid setup is also a narrow spread: management’s early 2027 rate and trend ranges imply anything from modest margin recovery to no improvement before enrollment and acuity effects. State rate recognition is not guaranteed to keep pace with claims, particularly if budget pressure delays adjustments.

Near term, the risk is that investors capitalize the >$9.50 preliminary EPS building blocks before February guidance validates trend, enrollment attrition, and Florida progress. Over 1–3 months, Georgia/Texas court timing is a volume and operating-leverage catalyst; delay into 2028 would defer revenue and some embedded earnings, not necessarily erase the awards. Over 6–18 months, work requirements create a two-sided effect: fewer members reduce premium scale, while a sicker retained pool can raise MCR unless rates capture that acuity promptly. Medicaid peers face similar rate-setting dynamics, but MOH’s unusually large Florida ramp makes its execution risk more company-specific. The contrarian point: a 2027 margin turn may be real, but the company’s own building blocks do not yet require legacy MCR improvement—so the upside case is not proof that the trough has passed.

Key Decisions for Investors

• Avoid chasing the preliminary 2027 EPS bridge. Keep MOH underweight versus a diversified managed-care basket into February guidance; the near-term risk/reward is skewed to execution and claims-estimate disappointment rather than unmodeled legacy-margin upside.
• For a defined-risk bearish expression, consider a 3–6 month MOH put spread only if the stock rallies on the EPS bridge without corroborating operating data; avoid initiating after a sharp selloff. Reassess if the February outlook confirms trend at or below the rate run-rate and shows Florida tracking to breakeven.
• Track Florida contract MCR and pre-tax progression, Medicaid trend versus realized rate increases, and days in claims payable. A sustained claims-payable increase or Florida losses failing to narrow would falsify the recovery thesis; stable reserves, improving Florida economics, and explicit legacy MCR improvement in February would weaken the bearish view.
• Treat Georgia/Texas court outcomes as timing catalysts, not certain incremental earnings: verify implementation dates and the associated premium/earnings contribution before underwriting the deferred opportunity.